NCT00373373已完成2 期
A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
University Hospital Muenster18 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 18
- 主要终点
- Median Event Free Survival of all AML patients
研究概览
简要总结
The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 61 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML)
- •Bone marrow aspirate or biopsy must contain >= 20% blasts of all nucleated cells, with the exception of AML FAB M6, where >= 30% of non-erythroid cells must be leukemic blasts
- •Age >= 61 years
- •Informed consent, personally signed and dated to participate in the study
- •Male patients enrolled in this trial must use adequate barrier birth control measures during the course of the Sorafenib treatment and for at least 3 months after the last administration of Sorafenib
排除标准
- •Central nervous system manifestation of AML
- •Cardiac Disease: Heart failure NYHA III° or IV°; active coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- •Chronically impaired renal function (creatinin clearance < 30 ml/min)
- •Chronic pulmonary disease with relevant hypoxia
- •Inadequate liver function (ALT and AST >= 2.5 x ULN)
- •Total bilirubin >= 1.5 x ULN
- •Resting blood pressure (BP) consistently higher than systolic 160 mmHg and/or diastolic 95 mmHg
- •Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol
- •Uncontrolled active infection
- •Concurrent malignancies other than AML
- •Previous treatment of AML except hydroxyurea and up to 2 days <= 100 mg/m²/d cytarabine
- •Known HIV and/or hepatitis C infection
- •Evidence or history of CNS disease, including primary or metastatic brain tumors, seizure disorders
- •Thrombotic or embolic events such as cerebrovascular accident or pulmonary embolism within 1 year of study entry
- •Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy
- •History of organ allograft
- •Concomitant treatment with kinase inhibitors, angiogenesis inhibitors and Myelotarg
- •Patients with major surgery, open biopsy or significant traumatic injury within 4 weeks of start or first dose
- •Serious, non-healing wound, ulcer or bone fracture
- •Allergy to study medication or excipients in study medication
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- •Patients who are not eligible for standard chemotherapy
研究组 & 干预措施
A
Placebo Comparator
Chemotherapy + Placebo
干预措施: Placebo (Drug)
B
Active Comparator
Chemotherapy + Sorafenib
干预措施: Sorafenib (Drug)
结局指标
主要结局
Median Event Free Survival of all AML patients
次要结局
- Median Event Free Survival of AML patients with Flt3-ITD mutations
- Median Event Free Survival of the patients in each of the four strata (Flt3 Non-ITD/NPM1 WT, Flt3 Non-ITD/NPM1 mut, Flt3 ITD/NPM1 WT, Flt3 ITD/NPM1 mut)
- Median Overall Survival of AML patients with Flt3-ITD mutations
- Median Overall Survival of all AML patients
- Rate of Complete Remission in all AML patients
- Toxicity
- Rate of Molecular Remission in all AML patients
- Evidence of Minimal Residual Disease in all AML patients
- Development of Biomarkers indicating the course of disease
研究者
研究点 (18)
Loading locations...
相似试验
已完成
2 期
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular CancerHepatocellular CancerNCT00813293Beth Israel Deaconess Medical Center20
撤回
2 期
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid CarcinomaMedullary Thyroid CarcinomaNCT01736878Eanm Research Ltd
已完成
2 期
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).Carcinoma, HepatocellularNCT00855218Bayer307
已完成
3 期
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast CancerBreast CancerNCT01234337Bayer537
已完成
3 期
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCarcinoma, HepatocellularNCT00492752Bayer226